First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan.
Aims. Patients with chronic kidney disease (CKD) and Helicobacter pylori (H. pylori) infection have a higher incidence of gastroduodenal diseases and therefore are recommended to receive eradication therapies. This study aimed to assess the efficacy of a 7-day standard triple therapy in patients wit...
| Publicado en: | BioMed Research International Vol. 2017; pp. 1 - 8 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
12/11/2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126688692&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 126688692 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 12/11/2017 vid: 2017 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 126688692 126688692 126688692 10.1155/2017/3762194 126688692 ppf: 1 ppct: 7 formats: fmt: @attributes: type: P tig: atl: First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan. aug: au: Liang, Chih-Ming Chiu, Chien-Hua Wang, Hsing-Ming Tai, Wei-Chen Yao, Chih-Chien Tsai, Cheng-En Kuo, Chung-Mou Chiu, Yi-Chun Wu, Keng-Liang Lee, Chen-Hsiang Tsai, Kai-Lung Huang, Chih-Fang Chuah, Seng-Kee affil: Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan sug: subj: Disease Eradication Helicobacter Pylori Kidney Failure, Chronic Diagnosis Patient Care Human Taiwan Geographic Locations Helicobacter Infections Therapy Incidence Peptic Ulcer Risk Factors Glomerular Filtration Rate Evaluation Patient Selection Control Group Kidney Failure, Chronic Complications Protocols Treatment Outcomes Evaluation Data Analysis Software Middle Age Aged Male Female Middle Aged: 45-64 years Aged: 65+ years Male Female ab: Aims. Patients with chronic kidney disease (CKD) and Helicobacter pylori (H. pylori) infection have a higher incidence of gastroduodenal diseases and therefore are recommended to receive eradication therapies. This study aimed to assess the efficacy of a 7-day standard triple therapy in patients with CKD (eGFR < 60 ml/min/1.73 m2) and to investigate the clinical factors influencing the success of eradication. Methods. A total of 758 patients with H. pylori infection receiving a 7-day standard first-line triple therapy between January 1, 2013, and December 31, 2014, were recruited. Patients were divided into two groups: CKD group (N=130) and non-CKD group (N=628). Results. The eradication rates attained by the CKD and non-CKD groups were 85.4% and 85.7%, respectively, in the per-protocol analysis (p=0.933). The eradication rate in CKD stage 3 was 84.5% (82/97), in stage 4 was 88.2% (15/17), and in those who received hemodialysis was 87.5% (14/16). There were no significant differences in the various stages of CKD (p=0.982). The adverse events were similar between the two groups (3.1% versus 4.6%, p=0.433). Compliance between the two groups was good (100.0% versus 99.8%, p=0.649). There was no significant clinical factor influencing the H. pylori eradication rate in the non-CKD and CKD groups. Conclusions. This study suggests that the H. pylori eradication rate and adverse rate in patients with CKD are comparable to those of non-CKD patients. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|